相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
Emmanuel Seront et al.
BJU INTERNATIONAL (2016)
Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice
Julie Klein et al.
KIDNEY INTERNATIONAL (2016)
Dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer
Yu-Hsuan Chen et al.
CANCER LETTERS (2015)
Cyclic nucleotide signalling in kidney fibrosis
Elisabeth Schinner et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine
Martin Pejchinovski et al.
PROTEOMICS CLINICAL APPLICATIONS (2015)
Cellular Mechanisms of Tissue Fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis
David Lu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2014)
FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K-AKT Pathway
Aifu Lin et al.
CANCER RESEARCH (2014)
Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
Carlos Rodrigo Gil del Alcazar et al.
CLINICAL CANCER RESEARCH (2014)
NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
Du G. Moon et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Activation of the PI3K/mTOR Pathway Is Involved in Cystic Proliferation of Cholangiocytes of the PCK Rat
Xiang Shan Ren et al.
PLOS ONE (2014)
Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial
Lori Berk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Dose-Dependent Effects of Sirolimus on mTOR Signaling and Polycystic Kidney Disease
Zlata Novalic et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses
Bipasha Mukherjee et al.
NEOPLASIA (2012)
Limitations in Small Intestinal Neuroendocrine Tumor Therapy by mTor Kinase Inhibition Reflect Growth Factor-Mediated PI3K Feedback Loop Activation via ERK1/2 and AKT
Bernhard Svejda et al.
CANCER (2011)
Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Ning Jin et al.
CLINICAL CANCER RESEARCH (2011)
mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease
Franck Belibi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level?
G. Canaud et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia
Aldo M. Roccaro et al.
BLOOD (2010)
Compensatory activation of Akt in response to mTOR and Raf inhibitors - A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Kathrin Zitzmann et al.
CANCER LETTERS (2010)
Rapamycin Ameliorates PKD Resulting from Conditional Inactivation of Pkd1
Jonathan M. Shillingford et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Cyclic AMP Controls mTOR through Regulation of the Dynamic Interaction between Rheb and Phosphodiesterase 4D
Hyun Wook Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Chronic Inhibition of the mTORC1/S6K1 Pathway Increases Insulin-Induced PI3K Activity but Inhibits Akt2 and Glucose Transport Stimulation in 3T3-L1 Adipocytes
Alain Veilleux et al.
MOLECULAR ENDOCRINOLOGY (2010)
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Andreas L. Serra et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Gerd Walz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Comprehensive human urine standards for comparability and standardization in clinical proteome analysis
Harald Mischak et al.
PROTEOMICS CLINICAL APPLICATIONS (2010)
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells
Jun Sunayama et al.
STEM CELLS (2010)
Polycystic Kidney Disease
Peter C. Harris et al.
ANNUAL REVIEW OF MEDICINE (2009)
Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis
Cleo S. Bonnet et al.
HUMAN MOLECULAR GENETICS (2009)
Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis
Kristen Pollizzi et al.
MOLECULAR CANCER (2009)
CAPILLARY ELECTROPHORESIS-MASS SPECTROMETRY AS A POWERFUL TOOL IN BIOMARKER DISCOVERY AND CLINICAL DIAGNOSIS: AN UPDATE OF RECENT DEVELOPMENTS
Harald Mischak et al.
MASS SPECTROMETRY REVIEWS (2009)
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
Saskia M. Brachmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease
Ming Wu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
Chiaki Tanaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1
Klaus Piontek et al.
NATURE MEDICINE (2007)
Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease
Ming Wu et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2007)
A functional floxed allele of pkd1 that can be conditionally inactivated in vivo
KB Piontek et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
分享论文
